Top Page
Zhong Ji Longevity Science Group Limited
(0767)
Zhong Ji Longevity Science Group Limited (0767) vs. iShares MSCI Hong Kong ETF (EWH)
Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model
Zhong Ji Longevity Science Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 174.06M | 168.63M | 64.99M | 89.44M | 62.98M | 81.41M |
| Gross Profit | 174.06M | 57.41M | 56.28M | 79.41M | 49.40M | 71.83M |
| EBITDA | -17.56M | -29.96M | 13.02M | 15.99M | 16.13M | -11.89M |
| Net Income | -46.43M | -34.73M | 2.31M | -904.00K | 6.05M | -11.49M |
Balance Sheet | ||||||
| Total Assets | 509.39M | 525.63M | 509.25M | 484.84M | 517.50M | 478.24M |
| Cash, Cash Equivalents and Short-Term Investments | 30.04M | 47.84M | 81.08M | 60.07M | 19.44M | 40.80M |
| Total Debt | 12.77M | 19.11M | 20.20M | 11.76M | 12.93M | 8.70M |
| Total Liabilities | 77.85M | 125.49M | 78.79M | 63.99M | 46.78M | 23.35M |
| Stockholders Equity | 404.98M | 373.42M | 403.40M | 393.83M | 443.75M | 428.83M |
Cash Flow | ||||||
| Free Cash Flow | -106.77M | -61.76M | 15.28M | 11.08M | -40.51M | -192.89M |
| Operating Cash Flow | -104.97M | -61.05M | 15.28M | 12.11M | -39.62M | -191.54M |
| Investing Cash Flow | 10.45M | 11.47M | 382.00K | 16.59M | 2.91M | 70.11M |
| Financing Cash Flow | 20.18M | 15.17M | 6.02M | -7.45M | 3.44M | -1.43M |
Zhong Ji Longevity Science Group Limited Technical Analysis
Zhong Ji Longevity Science Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$344.00M | 7.03 | 5.24% | 5.70% | -1.47% | 2.86% | |
68 Neutral | HK$342.20M | 5.66 | 2.75% | 4.88% | -12.94% | -15.93% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
58 Neutral | HK$324.66M | 11.16 | 1.12% | ― | -9.75% | -81.16% | |
54 Neutral | HK$337.43M | -6.26 | -11.40% | ― | 121.54% | -8360.00% | |
52 Neutral | HK$224.58M | 7.47 | 4.83% | ― | -25.74% | ― |
Zhong Ji Longevity Science Group Limited Corporate Events
Zhong Ji Longevity Science Group Limited announced the resignation of two executive directors, Mr. Yan Yifan and Ms. Cao Xie Qiong, with Mr. Yan Li stepping in as the new CEO. The company faces a compliance issue due to a lack of gender diversity on its board, as required by the Hong Kong Stock Exchange’s Listing Rules. Efforts are underway to appoint a female director by January 2026 to meet these requirements, reflecting the company’s commitment to enhancing board diversity.
The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.
Zhong Ji Longevity Science Group Limited announced supplemental information related to its 2024 Annual Report, detailing the use of net proceeds from a subscription. The company fully utilized approximately HK$19.4 million, with 60% allocated to expanding its longevity science and biomedical products trading businesses, and 40% for general working capital. No share options were granted under the 2022 Share Option Scheme during the fiscal year 2024.
The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.
Zhong Ji Longevity Science Group Limited announced the resignation of Mr. Yan Yifan and Ms. Cao Xie Qiong from their executive director roles, with Mr. Yan also stepping down as CEO to focus on personal commitments. Mr. Yan Li, an experienced executive in the medical technology field and already serving as the company’s chairman, has been appointed as the new CEO. This leadership change may impact the company’s strategic direction and operational focus, as Mr. Yan Li brings significant expertise in biotechnology and management.
Zhong Ji Longevity Science Group Limited has announced the composition of its board of directors and the roles within its five board committees. This announcement outlines the leadership structure, which includes executive, non-executive, and independent non-executive directors, and highlights the company’s commitment to strong governance and strategic oversight.
Zhong Ji Longevity Science Group Limited announced a collaboration agreement between its subsidiary, Zhongli (Hainan) Life Science Technology Co., Ltd., and Hainan Boao Super Hospital Co., Ltd. to establish the International Precision Oncology Medical Center. This collaboration aims to leverage Hainan Boao’s advanced medical facilities and Zhongli’s expertise in longevity health services to provide comprehensive diagnostic and treatment services. The partnership is expected to enhance the company’s positioning in the health and longevity science market, capitalizing on the growing demand for innovative health solutions.
Zhong Ji Longevity Science Group Limited has announced an extension of the expiry date for its Memorandum of Understanding (MOU) regarding the potential acquisition of Asian Integrated Cell Laboratory Limited. This extension, until December 2, 2025, allows more time for due diligence and assessment. The target company collaborates with Bright Cells Inc. to conduct FDA-approved clinical research on stem cells, aiming to develop treatments for aging-related frailty and premature ovarian failure across various regions. The acquisition, if completed, could significantly impact the company’s market position and stakeholder interests.
Zhong Ji Longevity Science Group Limited announced its interim results for the first half of 2025, revealing a 13.1% increase in revenue to HK$48.0 million compared to the previous year. Despite the revenue growth, the company faced a significant decrease in gross profit by 51.8% and recorded a loss before tax of approximately HK$11.5 million. The company’s net assets, however, increased by 7.9% to HK$431.5 million. No interim dividend was recommended for the period.
Zhong Ji Longevity Science Group Limited has announced a board meeting scheduled for August 28, 2025, to consider and approve the interim results for the first half of 2025 and discuss the potential payment of an interim dividend. This meeting is a significant event for the company as it will address key financial outcomes and strategic decisions that could impact stakeholders and the company’s market position.
Zhong Ji Longevity Science Group Limited announced a memorandum of cooperation between its subsidiary, Blooming Faith Development Limited, and Shenzhen Zhonghang Health and Fashion Group Co., Ltd. This collaboration aims to enhance their offerings in the longevity testing and management sector, leveraging Blooming Faith’s product and management expertise and Zhonghang Health’s customer resources and marketing channels. The partnership is expected to strengthen the company’s position in the growing health and longevity science market, which is increasingly attracting affluent consumers worldwide.
Zhong Ji Longevity Science Group Limited announced the withdrawal of a winding-up petition against the company, following approval from the Hong Kong court. This development may have implications for the company’s stakeholders, as it alleviates immediate legal pressures and could stabilize investor confidence.